The leading global business development database Biotechgate presents its 2019 trend report for the Dutch life sciences market. The annual trend report shows that the Netherlands is on track to become a world leading life sciences cluster in 2030.
The total number of biotech companies is growing steadily to 470 in 2019. Oncology remains the most prominent therapeutic area, followed by neurology and infectious diseases. With many ground-breaking companies and world-class universities, the Netherlands is the perfect location for biopharmaceutical innovation in Europe.
Over the years, the Netherlands evolved into a fertile breeding ground for research and development. The number of products in our clinical pipeline slightly increased compared to 2018. At the moment there are 41 phase I, 49 phase II and 13 phase III studies in development. On top of that, almost 100 products are investigated in a preclinical setting. These numbers promise a bright future ahead.
HollandBIO’s managing director Annemiek Verkamman is happy to see the analysis confirms the leading position of the Dutch life sciences sector. “With top-notch scientists, outstanding research and education and great entrepreneurial spirit, we established our leading position in Europe. Add to that the recent relocation of the EMA, and it becomes clear that the Netherlands has what it takes to become one of the world’s top biotech clusters by 2030!”
Biotechgate is a global business development database containing nearly 55,000 high-quality company profiles including company descriptions, contact information, product pipeline information, financing rounds and more. Biotechgate is owned and operated by Venture Valuation AG, a Zurich-based company specializing in independent assessment and valuation of technology-driven companies in high-growth industries.Whether you are looking to partner with a Dutch company or looking for a specific service, you’ll find the most complete overview of the Dutch life sciences sector at www.dutchbiotech.com.